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Quinolone Safety
and Efficacy More
Important than
Potency 
To the Editor: In a recent article,
Scheld defines two principles for
appropriate quinolone use based on
the goal of maintaining class efficacy,
namely avoiding unnecessary antimi-
crobial drug therapy and “using the
agents with optimal activity against
the expected pathogens” (1). He pres-
ents a large body of evidence support-
ing an inverse correlation between
quinolone activity and the selection of
antimicrobial drug resistance. On the
basis of this concept, Scheld favors
ciprofloxacin for known or suspected
Pseudomonas aeruginosa infection
and moxifloxacin for infections in
which  Streptococcus pneumoniae is
likely, including community-acquired
pneumonia (CAP). Preventing the
emergence of antimicrobial drug
resistance is certainly an important
goal in drug therapy decision-making.
However, this goal should be bal-
anced by the clinical criteria of safety
and efficacy.
Serious adverse drug effects in
patients led to the withdrawal or
restriction of four quinolones in the
past decade (temafloxacin, grepa-
floxacin, trovafloxacin, and spar-
floxacin). Safety may differ substan-
tially among the quinolones discussed
in Scheld’s review (ciprofloxacin, lev-
ofloxacin, moxifloxacin, and gati-
floxacin). On the basis of spontaneous
reports to the U.S. Food and Drug
Administration (FDA), gatifloxacin is
associated with a higher rate of tor-
sades de pointes than ciprofloxacin or
levofloxacin (p = 0.001) (2). Torsades
cases have been reported in associa-
tion with moxifloxacin, but their rate
cannot be estimated with any preci-
sion by using FDA spontaneous
reporting data because of the relative-
ly small number of U.S. prescriptions
(2). In a crossover study, a single oral
dose of moxifloxacin 800 mg was
associated with greater QT interval
prolongation (16–18 milliseconds)
than ciprofloxacin 1,500 mg (2–5 mil-
liseconds) or levofloxacin 1,000 mg
(4–5 milliseconds) (3). Gatifloxacin
has been associated with alterations in
glucose metabolism, both in prospec-
tive trials and in postmarketing sur-
veillance. Gatifloxacin underwent two
“safety-related drug labeling
changes” in 2001 and is the only
quinolone that carries a “warning”
about disturbances in glucose metabo-
lism. Gemifloxacin was approved
after Scheld’s review and has pharma-
codynamic potency similar to moxi-
floxacin against S. pneumoniae.
Gemifloxacin is associated with a
high rate of rashes, especially in
women <40 years of age.
Serious but uncommon adverse
side effects may not be recognized
until drugs are used in large popula-
tions (4). More than 100 million pre-
scriptions were written for terfenadine
and astemizole before they were with-
drawn from the market because of tor-
sades and sudden death. On the basis
of the number of U.S. prescriptions in
the past decade (January 1993–
December 2002), patient experience
with ciprofloxacin (119 million pre-
scriptions) and levofloxacin (44 mil-
lion) is larger than with gatifloxacin
(8 million) or moxifloxacin (5 mil-
lion) (5–7).
The clinical efficacy of cipro-
floxacin and levofloxacin is better
established for a broad range of indi-
cations in comparison to the newer
agents. A full discussion of the litera-
ture is beyond the scope of this letter.
A simple MEDLINE (U.S. National
Library of Medicine, Bethesda, MD)
search in April 2003 provided the fol-
lowing raw numbers of peer-
reviewed, randomized, controlled tri-
als reporting clinical outcomes: >200
trials using ciprofloxacin, 28 using
levofloxacin, 13 using moxifloxacin,
7 using gatifloxacin, and 6 using
gemifloxacin (search terms, inclusion
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criteria, and exclusion criteria avail-
able from the author). The quality of
these studies is quite variable, and
quality is certainly more important
than quantity. Most trials of the newer
agents were designed and funded by
industry. In general, ciprofloxacin and
levofloxacin have been studied in
patient populations with more severe
illnesses, including nosocomial infec-
tions, than the newer quinolones.
With the exception of a single moxi-
floxacin trial (8), the trials of the
newer quinolones have enrolled
patients with predominantly mild or
moderate community-acquired infec-
tions and low overall mortality rates.
Scheld provides a table that lists
case reports of clinical failures of lev-
ofloxacin for the treatment of pneu-
mococcal infections. Some cases were
associated with primary or secondary
levofloxacin resistance. These case
reports should not be surprising, since
CAP trials regularly identify clinical
failures regardless of the therapy cho-
sen. The rate of clinical failure is best
determined by data from prospective
trials rather than case reports. Both
levofloxacin and moxifloxacin have
performed well in patients with severe
pneumococcal infections, on the basis
of the rates of therapeutic success and
death (8–10).
Scheld’s choice of ciprofloxacin as
a component of combination therapy
for suspected P. aeruginosa infections
can be affirmed. Ciprofloxacin has
pharmacodynamic potency against P.
aeruginosa, a track record of safety in
large populations, and a large pub-
lished literature. Ciprofloxacin has
demonstrated efficacy in patient pop-
ulations with severe illnesses, includ-
ing nosocomial infections. 
Antimicrobial drug therapy deci-
sion-making for patients with CAP
and other respiratory tract infections
is much more complex. Individual
patient factors should be considered,
including the severity of illness,
coexisting illnesses, risk factors for
drug-resistant  S. pneumoniae, and
risk factors for specific adverse
effects. A respiratory quinolone will
be an appropriate choice for some
patients with CAP. Among the respi-
ratory quinolones, a wholesale switch
from levofloxacin to moxifloxacin,
on the basis of pneumococcal poten-
cy alone, would be premature.
Clinicians should use newer
quinolones cautiously until their safe-
ty has been established in large
patient populations.
Richard Frothingham*
*Veterans Affairs Medical Center and Duke
University Medical Center, Durham, North
Carolina, USA
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Vancomycin-
resistant
Enterococcus 
faecalis in Serbia
To the Editor: First isolated in
France (1), vancomycin-resistant
enterococci (VRE) have become
pathogens of major importance, par-
ticularly in the United States (2).
Infections due to VRE are still
uncommon in most European coun-
tries (3). We report the first isolation
of high-level vancomycin-resistant
Enterococcus faecalis in Serbia. 
A 55-year-old woman was admit-
ted to the Clinic for Cardiovascular
Diseases, Belgrade, on April 1, 2002,
for aortobifemoral bypass surgery.
Three weeks after she was admitted to
the hospital, an infection developed in
the surgical wound and treatment with
trimethoprim-sulfamethoxazole
(160/800 mg q 12 h) was empirically
introduced. Bacteriologic analysis of
the wound swab sample showed a
methicillin-resistant strain of
Staphylococcus aureus, a multiresis-
tant strain of Acinetobacter sp., a com-
monly susceptible strain of
Enterococcus sp., and a VRE strain.
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